股票代码：******

Chairman Jing Yue's Notes on the Key Event of the 2022 Resilient City Development and Technology Emergency Seminar

Published:

2022-08-26

New Concepts Promote Technology Empowerment, New Models Build Safety Barriers

Chairman Jing Yue's Notes on the 2022 Resilient City Development and Technology Emergency Seminar Key Event

On August 21, the 2022 Resilient City Development and Technology Emergency Seminar was grandly held at the Shenzhen Talent Training Institute, hosted by the Southern University of Science and Technology Innovation and Entrepreneurship School and the Risk Analysis, Forecasting and Control Research Institute, organized by Jiangxi Biological Products Institute Co., Ltd., and guided by the Emergency Management Department's China Earthquake Emergency Rescue Center and Shenzhen Emergency Bureau.

The seminar, themed "Technology Empowerment, Safe Development," was attended by 4 academicians and more than 50 well-known professors, experts, and scholars. The discussions mainly focused on new concepts in urban risk prevention and control, new models of grassroots social governance, new equipment in disaster relief and rescue, and new technologies in emergency management. As one of the organizers, the company leadership attached great importance to this meeting. Chairman Ms. Jing Yue attended the entire event and delivered a speech, fully demonstrating the company's mission and responsibility as a high-tech enterprise providing biological immune emergency drugs for the prevention and treatment of severe diseases, contributing valuable ideas and insights to promote biopharmaceutical technological innovation in enhancing urban biosafety and establishing an efficient major emergency response system.

(Speech by Chairman Jing)

At the meeting, Chairman Ms. Jing Yue delivered a keynote speech themed "Building a Rapid Drug Response Platform for Treating Major Infectious Diseases" (hereinafter referred to as the Rapid Drug Response Platform). She proposed that the company will center on the Rapid Drug Response Platform to build the "Two Repositories and One Platform." That is, based on the Rapid Drug Response Platform, establish a Major Infectious Disease Research Institute and a Standard Sample Library of Antigens and Antibodies, forming an integrated arsenal for prevention, treatment, and diagnosis of infectious or sudden infectious diseases, and establish an integrated "production-medical-research-application" platform.

Chairman Jing elaborated in detail that biosafety is an important component of a safe and resilient city and has become a key evaluation indicator for such cities. The most critical aspect of biosafety is ensuring people's life safety. Therefore, to build a safe and resilient city, constructing a "Rapid Drug Response Platform for Treating Major Infectious Diseases" has significant practical importance.

(Chairman Jing's detailed introduction of the platform concept)

Regarding the platform construction concept, Chairman Jing introduced: the company will leverage multiple technological advantages to initiate the construction of the Rapid Drug Response Platform, centering on the "polyclonal antibodies" in horse anti-serum as the core technology. By collecting and analyzing different pathogens, it will develop rapid emergency treatment drugs and form a complete drug emergency support system. It is hoped that relying on the Rapid Drug Response Platform, Jiangsheng's capabilities can quickly develop efficient, broad-spectrum, and economical high-quality drugs for diseases that harm people's health but currently lack specific drugs, solving the clinical problem of lacking specific treatment methods for such diseases. This will provide effective, affordable, and accessible specific therapeutic drugs for the general public and people worldwide. Moreover, it is hoped that the platform will promote regional biosafety and support the construction of resilient cities.

Finally, Chairman Jing also gave a detailed introduction to the platform's technical advantages, composition and functional positioning, and future development plans to the attending experts, and engaged in in-depth exchanges and discussions on some issues related to platform construction. The experts fully affirmed the important significance of the Rapid Drug Response Platform in building a biosafety barrier to protect human health. As a company with over 50 years of history and a strong sense of social responsibility, the company will continue to actively promote the construction of the Rapid Drug Response Platform to achieve its early launch and contribute Jiangsheng's strength to biosafety and resilient city construction!

Commend all employees of Jiangxi Biology for wholeheartedly fighting the epidemic and fully ensuring production

Jiangxi Bio assists in the successful holding of the automated external defibrillator donation ceremony

Add:

Address: No. 198 Huoju Avenue, Jinggangshan Economic & Technological Development Zone, Ji’an, Jiangxi, China

Board Office:

Domestic Sales:

International Sales: